GlassScriptPhysician profile
Aishah Aslam
NPI 1518305671
$1,665.95
in general payments reported to CMS, 2019-2025
17 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $50.15 · 2021: $144 · 2022: $157 · 2023: $563 · 2024: $367 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,182.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $246.06 | 2023-2025 | Camzyos |
| Abbott Laboratories | $235.56 | 2021-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Kestra Medical Technology Services, INC. | $189.34 | 2023-2025 | Assure Wcd |
| Edwards Lifesciences Corporation | $188.74 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Actelion Pharmaceuticals US, INC. | $168.46 | 2019-2023 | Opsumit, Uptravi |
| Cvrx, INC. | $134.31 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $98.16 | 2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.41 | 2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.99 | 2020-2022 | |
| Pfizer INC. | $70.14 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $49.60 | 2022 | |
| Amgen INC. | $27.77 | 2023 | Repatha |
| Kiniksa Pharmaceuticals, LTD. | $23.84 | 2023 | Arcalyst |
| Novo Nordisk INC | $20.00 | 2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $19.46 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $17.79 | 2023 | |
| Seagen INC. | $17.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aishah Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.